Multiple Myeloma: clinical and laboratory manifestations and main treatment regimens Hospital de San José de Bogotá DC. 2003 to 2010
Mieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010
Show authors biography
Multiple myeloma is an incurable cancer of the plasma cells featuring disabling morbidity due to its many possible symptoms and high mortality rate. It affects all races and geographic regions. The average age at diagnosis is 66 years. Only 10% are under age 50 and 2% under 40. Objective: to describe the clinical and laboratory manifestations and main first-line therapies of patients managed and treated at Hospital de San José, Bogotá DC, between January 2003 and December 2010. Method: a retrospective cohort study of patients with diagnosed symptomatic multiple myeloma aged more than 18 years based on data compiled from clinical records. Results: thirty-nine (39) patients were diagnosed in an 8-year period, 59% were men with a mean age of 59.7 years (SD 10.7). Seventy percent (70%) were considered candidates for a transplant and this procedure was actually performed in 33.0% (n= 7/21). The chemotherapy regimen most commonly used was a thalidomide--dexamethasone combination (23%). The most frequently observed response to therapy was a very good partial response (40.9%) and 23.7% achieved at least one complete response.
Article visits 532 | PDF visits 522
Downloads
1. Ries LAG, Eisner MP, Kosary C, et al. SEER Cancer Statistics Review, 1975- 2001. Betbesda, MD, National CancerInstitute. 2004.
2. Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma. 1998 Aug;30(5-6):493-50I.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225.
4. Kyle RA, Gertz M, Witzig TE, et al. Review of 1027 patients with newly diag nosed multiple myeloma. Mayo Clin Proc. 2003;78:21.
5. Ferlay J, Shin H. Bray F, Fomrnn D, Mathers C PD. Estimates of worldwide bur den of cancer in 2008: GLOBOCAN 2008. Int J Clin Pract. 20l 0;127:2893-917.
6. Instituto Nacional de Cancerología. Anuario Estadístico. 2009;7.
7. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410.
8. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of under termined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatrnent. Mayo Clin Proc. 2006;8 I :693.
9. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, et al. Management of newly diagnosed symptomalic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009 Dec;84(12):1095-IJ0.
10. Greipp PR, San MJ, Durie BG, et al. lntemational staging system far multiple myeloma. J Clin Oncol. 2005;23:3412.
11. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurren! genomic aberrations in myeloma. Blood. 2003;101:4569.
12. Durie BG, Harousseau JL, Miguel JS, et al. International unifarm response crite ria for multiple myeloma. Leukemia. 2006;20:1467.
13. Munshi NC. Plasma cell disorders: an historical perspective. Hematology. 2008;2008(297).
14. Anderson KC, Faber E, Samio G, Alsina M, Huff CA, Stockerl-Goldstein KE, et al. NCCN Clinical Practice Guidelines in Oncology. National Compreheosive Cancer Network. 2011;1.201I:1-53.
15. Atta! M, Harousseau JL, Stoppa AM, Sotto J, Fuzibet J, Rossi JF, et al. A pro spective, randomized tria! of autologous bone marrow transplantation and che motherapy in multiple myeloma. lntergroupe Francais du Myélome. N Engl J Med. l996;335(2):91-7.
16. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011;8(8):479-81.
17. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, et al. Dose-intensive melphalan with stem cell support (MELI00) is superior to stan dard treatrnent in elderly myeloma patients. Blood. 1999;94(4):1248-53.
18. Kyle RA, Themeau TM. Rajkumar SV, el al. Incidence of multiple myeloma in Olmsled County, Minnesota: Trend over 6 decades. Cancer. 2004;101:2667.
19. Kapoor P, Rajkumar SV. Update on risk stratification aod treatment of newly diagnosed multiple myeloma. Int J Hemalol. 2011;JO:1007.
20. Barlogie B, Alexanian R, Dicke KA, el al. High-dose chemoradiotherapy and autologous bone marrow transplantation far resistant multiple myeloma. Br J Haematol. l 987;66(1):55-62.
21. Alexanian R, Weber D, Giralt S, Delasalle K, Smith T, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001;27(10):1037-43.
22. Singhal S, Mehla J, Desikan R, el al. Antitumor activity of thalidomide in refrac tory multiple myeloma. N Engl J Med. 1999;341:1565-71.
23. Cavo M, Zamagni E, Tasi P, Taccetti P, Cellini C, Canning C. Superiority of thalidomide and dexamethasone over vincristine - doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation far mul tiple myeloma. Blood. 2005;106:35-9.
24. Rajkumar SV. Multiple myeloma: the death of VAD as initial therapy. Blood. 2005;106:2-3.
Information
Keywords
